Across TCGA pan-cancer cohorts, ZNF267 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF267 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF267 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF267 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where ZNF267 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.763	1.000	.003	24	view →
GBM	DFS	Quartile	All	0.603	0.901	.030	5	view →
LSCC	OS	Median	III,IV	0.928	0.523	.035	3	view →
HNSC	DFS	Median	IV	0.771	0.517	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF267 tumor-vs-normal RNA expression · all ZNF267 data types